ETON — Eton Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $95.30m
- $79.29m
- $31.64m
- 53
- 36
- 70
- 52
Annual income statement for Eton Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.959 | 0.039 | 21.8 | 21.3 | 31.6 |
| Cost of Revenue | |||||
| Gross Profit | 0.506 | -0.247 | 19 | 14.3 | 21.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 19.6 | 27.1 | 23 | 29.5 | 32.8 |
| Operating Profit | -18.6 | -27.1 | -1.13 | -8.26 | -1.19 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -18.3 | -28 | -1.96 | -9.02 | -0.689 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -18.3 | -28 | -1.96 | -9.02 | -0.936 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -18.3 | -28 | -1.96 | -9.02 | -0.936 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -18.3 | -28 | -1.96 | -9.02 | -0.936 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.03 | -1.33 | -0.099 | -0.359 | -0.036 |